ALISO VIEJO, Calif., Oct. 17, 2007 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SenoSonix(tm) System, an integration of its EnCor(r) breast biopsy system with a state-of-the-art ultrasound imaging system. The device incorporates SenoRx’s proprietary EnCor vacuum-assisted biopsy technologies with an ultrasound system developed and sold by Ultrasonix Medical Corporation of Canada. SenoRx and Ultrasonix have enjoyed a close working relationship, jointly developing the technology that facilitates the integration of the two products. The product will be branded SenoSonix(tm) and marketed as SenoSonix(tm) with EnCor Inside.
